Nash

Akero Therapeutics Appoints Judy Chou, Ph.D., to its Board of Directors

Retrieved on: 
Wednesday, July 14, 2021
Medical specialties, Hepatitis, Clinical medicine, Health care, Steatohepatitis, Non-alcoholic fatty liver disease, Nash

(Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced the appointment ofJudy Chou, Ph.D., to its board of directors as an independent director.

Key Points: 
  • (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced the appointment ofJudy Chou, Ph.D., to its board of directors as an independent director.
  • "Akero is fortunate to welcome Dr. Chou and benefit from her strategic insights, particularly as our investigational NASH drug efruxifermin progresses in the clinic.
  • Dr. Chou is currently President & CEO of AltruBio, Inc., a company focused on developing novel therapeutics for immunological diseases.
  • Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies.

Standigm Secures Strategic Investment from SK Chemicals for Expanding its AI-Drug Development Capacity

Retrieved on: 
Friday, July 2, 2021
Research, General Health, Pharmaceutical, Data management, Technology, Clinical trials, Science, Chemicals, Plastics, Biotechnology, Other Technology, Health, Other Science, Manufacturing, Health sciences, Companies, Chaebol, SK Group, Drug discovery, Nash, Steatohepatitis

Standigm Inc. (Standigm), a leading workflow artificial intelligence (AI) drug discovery company, and SK Chemicals Co., Ltd (SK Chemicals), a life science and green chemicals company, announced today that they have signed a strategic partnership contract for collaboration regarding clinical development of Standigms AI-driven drug candidate for non-alcoholic steatohepatitis (NASH) and the foundation of Standigms Synthesis Research Center within the headquarters of SK Chemicals.

Key Points: 
  • Standigm Inc. (Standigm), a leading workflow artificial intelligence (AI) drug discovery company, and SK Chemicals Co., Ltd (SK Chemicals), a life science and green chemicals company, announced today that they have signed a strategic partnership contract for collaboration regarding clinical development of Standigms AI-driven drug candidate for non-alcoholic steatohepatitis (NASH) and the foundation of Standigms Synthesis Research Center within the headquarters of SK Chemicals.
  • This partnership was made in conjunction with SK Chemicals participation in Standigms pre-IPO round of fundraising.
  • Under the contract, SK Chemicals will collaborate with Standigm on the clinical development of the NASH drug candidate discovered by Standigm Insight, an AI-aided drug-repurposing platform, which is expected to enter clinical stage next year.
  • Moreover, Standigm plans to open its Synthesis Research Center in the headquarters of SK Chemicals next month.

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 18, 2021
Pharmaceutical, Health, Clinical trials, Medical specialties, Health, Hepatitis, Steatohepatitis, Non-alcoholic fatty liver disease, Clinical trial, Nash, Tropifexor

The "Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020" provides an overview of Non-Alcoholic Steatohepatitis (NASH) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis (NASH).
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

Can-Fite Receives Notice of Patent Allowance in China for NASH Treatment

Retrieved on: 
Wednesday, June 16, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Medical specialties, Clinical medicine, Medicine, Hepatitis, Steatohepatitis, Non-alcoholic fatty liver disease, Nash, Adenosine receptor, Metabolic syndrome, Adenosine, Seladelpar

This patent addresses the use of the A3 Adenosine Receptor (A3AR) ligand, the target receptor for Can-Fites drug platform technology, to reduce liver fat particularly in patients with non-alcoholic steatohepatitis (NASH).

Key Points: 
  • This patent addresses the use of the A3 Adenosine Receptor (A3AR) ligand, the target receptor for Can-Fites drug platform technology, to reduce liver fat particularly in patients with non-alcoholic steatohepatitis (NASH).
  • Namodenoson has been out licensed for the treatment of NASH in China and is part of a deal worth up to $74.5 million in milestone payments plus double-digit royalties.
  • The treatment market for NASH in China is projected to reach $6.4 billion by 2027 driven by increasing rates of obesity, metabolic syndrome, and diabetes.
  • This latest NASH patent adds to those already issued in the U.S., Europe, and South Korea, stated Can-Fite CEO Dr. Pnina Fishman.

Akero Therapeutics to Present Efruxifermin (EFX) Results Showing Histologic Improvement in EFX-Treated F4 Cirrhotic Patients as a Late-Breaker Oral Presentation at the 2021 International Liver Congress

Retrieved on: 
Tuesday, June 1, 2021
Medical specialties, Hepatitis, Clinical medicine, Non-alcoholic fatty liver disease, Cirrhosis, Steatohepatitis, Nash

We believe the consistency, magnitude and reproducibility of treatment effect sets efruxifermin apart in the NASH arena, said Kitty Yale, chief development officer of Akero.

Key Points: 
  • We believe the consistency, magnitude and reproducibility of treatment effect sets efruxifermin apart in the NASH arena, said Kitty Yale, chief development officer of Akero.
  • 2800 (Late breaker oral presentation), Efruxifermin (EFX) improved markers of fibrosis, liver injury and metabolism in F4 NASH patients with compensated cirrhosis, presented by Stephen Harrison, M.D.
  • Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies.
  • EFX is currently being evaluated in a Phase 2b clinical trial in NASH patients with F2/F3 fibrosis, the HARMONY study.

Akero Therapeutics to Present at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Friday, May 28, 2021
Hepatitis, Medical specialties, Clinical medicine, Steatohepatitis, Health care, Non-alcoholic fatty liver disease, Nash

SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics,Inc.

Key Points: 
  • SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics,Inc.
  • (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that members of the management team will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 2:30 p.m. (ET).
  • Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies.
  • Akero is headquartered in South San Francisco.

Global Non-Alcoholic Steatohepatitis Biomarker Market (2021 to 2028) - Featuring Allergan, AstraZeneca and Novartis Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, April 30, 2021
General Health, Health, Other Health, Medical specialties, Clinical medicine, Hepatitis, Medicine, Non-alcoholic fatty liver disease, Steatohepatitis, Fatty liver disease, Nash, Biomarker, Growth rate, Compound annual growth rate

b'The "Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028" report has been added to ResearchAndMarkets.com\'s offering.\nAccording to this report, the global market for non-alcoholic steatohepatitis (NASH) biomarker is estimated to exhibit growth at a CAGR of 21.28% during the years 2021-2028.\nThe growing occurrence of NASH among people, paired with the increasing incidence rate of metabolic comorbidities, is boosting the reviewed market on a growth path.

Key Points: 
  • b'The "Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028" report has been added to ResearchAndMarkets.com\'s offering.\nAccording to this report, the global market for non-alcoholic steatohepatitis (NASH) biomarker is estimated to exhibit growth at a CAGR of 21.28% during the years 2021-2028.\nThe growing occurrence of NASH among people, paired with the increasing incidence rate of metabolic comorbidities, is boosting the reviewed market on a growth path.
  • Besides, an increase in awareness regarding non-alcoholic fatty liver disease is opening new avenues for the NASH biomarker market over the projected period.\nHowever, side-effects of NASH therapeutics, along with the unavailability of specialized diagnostic tests for NAFLD, are hampering the expansion of the global market on a large scale.\nThe global market includes the Asia-Pacific, North America, Latin America, Europe, and the Middle East and Africa regions.\nThe Asia-Pacific is expected to observe the fastest growth rate in the non-alcoholic steatohepatitis biomarker market during the forecast period.
  • The region\'s growth can be attributed to the advancements in the healthcare infrastructure, the surge in the prevalence of NASH, and improvement in economic conditions.
  • Along with this, the growing healthcare awareness in emerging economies, including India and China, is expected to further influence the growth of the NASH biomarker market around the APAC region in the upcoming years.\n'

Axcella Announces Upcoming Oral Presentation at Digestive Disease Week (DDW) 2021

Retrieved on: 
Thursday, April 22, 2021
Health, Other Health, Other Science, Clinical trials, Research, Science, Biotechnology, Medical specialties, Hepatitis, Brain disorders, Clinical medicine, Anatomy, Hepatology, Steatohepatitis, Hepatic encephalopathy, Non-alcoholic fatty liver disease, Nash, Encephalopathy, Endogenous Metabolic Modulators (EMMs), Axcella, ENDOGENOUS METABOLIC MODULATORS (EMMS), AXCELLA

Abstracts are expected to appear on DDW\xe2\x80\x99s website in late April and in the May online supplement to Gastroenterology.

Key Points: 
  • Abstracts are expected to appear on DDW\xe2\x80\x99s website in late April and in the May online supplement to Gastroenterology.
  • ePosters and ePapers will be made available on this website during the congress.
  • The company\xe2\x80\x99s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways.
  • Axcella\xe2\x80\x99s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence.

Global NASH Markets, 2016-2020 & 2021-2026: Analysis by Drug Type, Sales Channel, Region, Country - Market Insights, Covid-19 Impact, Competition and Forecast - ResearchAndMarkets.com

Retrieved on: 
Friday, April 9, 2021
Pharmaceutical, Health, Clinical trials, Nash

The "Global NASH Market - Analysis By Drug Type, Sales Channel, By Region, By Country (2021 Edition): Market Insights, Covid-19 Impact, Competition and Forecast (2021-2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global NASH Market - Analysis By Drug Type, Sales Channel, By Region, By Country (2021 Edition): Market Insights, Covid-19 Impact, Competition and Forecast (2021-2026)" report has been added to ResearchAndMarkets.com's offering.
  • The Global NASH market valued at USD 3369.12 Million in the year 2020 is projected to grow due to growth in demand for ideal NASH therapeutics, surge in the prevalence of NASH, and expected launch of pipeline drugs during the forecast period.
  • Lifestyle interventions are the first-line approach to manage patients with NASH.
  • North America holds the major market share in 2020 as Canada's influence in global NASH markets cannot go unnoticed, which is propelling the regional industry outlook.

Steve Nash Joins BioSteel as Newest Ambassador Partner

Retrieved on: 
Thursday, April 8, 2021
National Basketball Association, Cars, Steve Nash, Nash Motors, Basketball, Nash, Patrick Mahomes, Brooklyn Nets, Ambassador automobile, Sports in the United States

NEW YORK, April 8, 2021 /PRNewswire/ -BioSteel today announced a multi-year deal with Brooklyn Nets coach and two-time MVP Steve Nash.

Key Points: 
  • NEW YORK, April 8, 2021 /PRNewswire/ -BioSteel today announced a multi-year deal with Brooklyn Nets coach and two-time MVP Steve Nash.
  • The partnership with BioSteel makes Nash the latest addition to the brand's impressive athlete and ambassador line-up including Luka Doncic and Patrick Mahomes.
  • The endorsement deal with BioSteel came about naturally for Nash, who is currently leading the first place Brooklyn Nets team.
  • Nash joins a growing list of top tier athletes and ambassadors who were consumers of the brand prior to being formally endorsed by BioSteel.